Fidia to Introduce Hymovis, Next-Generation Hyaluronan

By Julie A. Vetalice

At AAOS 2016, Fidia will commence U.S. launch of Hymovis® 2-injection highly viscoelastic hyaluronan, indicated to treat knee OA pain following an inadequate response to conservative non-pharmacologic therapy or analgesics.

FDA granted premarket approval to Hymovis in 3Q15.

Source: Fidia Farmaceutici S.p.A.


Bioventus recently gained multi-year exclusive U.S. distribution rights for GELSYN-3™, a 3-injection hyaluronic acid product.


Product Labels: Viscosupplement

Tags: Product Launch